{"schema_version":"secwatch.filing_event.v1","accession":"0001655759-24-000043","form_type":"8-K","ticker":"ARVN","cik":"0001655759","company_name":"ARVINAS, INC.","filed_at":"2024-04-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.449353+00:00","generated_at":"2026-06-04T00:05:01.192225+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Arvinas licenses ARV-766 to Novartis for $150M upfront; up to $1.01B in milestones","bullets":["Arvinas grants Novartis exclusive worldwide license to develop and commercialize ARV-766 for prostate cancer.","Novartis pays $150M upfront; Arvinas eligible for up to $1.01B in development, regulatory, and commercial milestones plus tiered royalties.","Asset purchase includes Arvinas' preclinical AR-V7 program sold to Novartis.","Novartis assumes full responsibility for global clinical development and commercialization of ARV-766.","Closing subject to HSR antitrust waiting period expiration or termination."],"urls":{"canonical":"https://secwatch.observer/filing/0001655759-24-000043","json":"https://secwatch.observer/filing/0001655759-24-000043.json","markdown":"https://secwatch.observer/filing/0001655759-24-000043.md","text":"https://secwatch.observer/filing/0001655759-24-000043.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1655759/000165575924000043/0001655759-24-000043-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1655759/000165575924000043/arvn-20240410.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T00:05:01.192225+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b8aeffd706bb0171346df6b4cfc38502d12133d4","claim":"ARVINAS, INC. entered into License Agreement with Novartis Pharma AG valued at $150.0 million upfront, up to $1.01 billion in milestones (effective 2024-04-10).","evidence_excerpt":"On April 10, 2024, Arvinas, Inc., a Delaware corporation (the “Company”), entered into a transaction (the “Transaction”), including both a license agreement (the “License Agreement”) and an asset purchase agreement (the “Asset Agreement”), with Novartis Pharma AG (“Novartis”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1655759/000165575924000043/0001655759-24-000043-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Novartis Pharma AG"},{"label":"Value","value":"$150.0 million upfront, up to $1.01 billion in milestones"},{"label":"Effective","value":"2024-04-10"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}